🔎 Trials Near Me

Gara Jalqabaatti › Dhukkubaa Harkaa Steatotic › New York › New York City

Qorannoo klinikaalii Dhukkubaa Harkaa Steatotic New York City, NY keessatti

Qorannoo 16 Dhukkubaa Harkaa Steatotic f New York City fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.

Takkalaa qorannoo (Ingiliffa)

Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

Namoota walitti qabaa jiraSadarkaa 3
  • 89bio Clinical Study Site, New York
  • 89bio Clinical Study Site, New York
Umuriin 18 hanga 75 · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT06419374

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

Namoota walitti qabaa jiraSadarkaa 3
  • 89bio Clinical Study Site, New York
Umuriin 18 hanga 80 · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT06318169

A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

Namoota walitti qabaa jiraSadarkaa 3
  • GSK Investigational Site, New York
Umuriin 18 hanga 75 · Saalaa hunda · Haaromfame 30-Ful-2026 · NCT07704892

Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States

Namoota walitti qabaa jiraSadarkaa 2
  • New York Presbyterian/Weill Cornell, New York
  • Columbia University Iriving School of Medicine, New York
Umuriin 18 hanga 75 · Saalaa hunda · Haaromfame 28-Ful-2026 · NCT05832229

A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition

Namoota walitti qabaa jiraSadarkaa 2
  • Columbia University Irving Medical Center, New York
Umuriin 18 hanga 75 · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT05519475

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

Namoota walitti qabaa jiraSadarkaa 3
  • NYU Langone Health, New York
  • IMA Clinical Research Manhattan, New York
  • New York Gastroenterology Associates, New York
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT07165028

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

Namoota walitti qabaa jiraSadarkaa 3
  • Akero Clinical Study Site, New York
  • Akero Clinical Study Site, New York
  • Akero Clinical Study Site, New York
Umuriin 18 hanga 80 · Saalaa hunda · Haaromfame 21-Ful-2026 · NCT06528314

A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

Namoota walitti qabaa jiraSadarkaa 3
  • GSK Investigational Site, New York
Umuriin 18 hanga 75 · Saalaa hunda · Haaromfame 17-Ful-2026 · NCT07221188

Human Models of Selective Insulin Resistance: Alpelisib, Part I

Namoota walitti qabaa jiraSadarkaa 1Hojjettoota fayyaa simatamoo
  • Columbia University Irving Medical Center, New York
Umuriin 18 hanga 70 · Saalaa hunda · Haaromfame 24-Hag-2026 · NCT06354088

A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease

Namoota walitti qabaa jiraSadarkaa 2
  • GSK Investigational Site, New York
Umuriin 18 hanga 70 · Saalaa hunda · Haaromfame 03-Hag-2026 · NCT06613698

A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

Namoota walitti qabaa jiraSadarkaa 3
  • GSK Investigational Site, New York
  • GSK Investigational Site, New York
Umuriin 18 hanga 75 · Saalaa hunda · Haaromfame 27-Ado-2026 · NCT07221227

A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH

Namoota walitti qabaa jiraSadarkaa 2
  • GSK Investigational Site, New York
Umuriin 18 hanga 75 · Saalaa hunda · Haaromfame 08-Ado-2026 · NCT06920043

Effect of Insulin Lowering on Lipogenesis

Namoota walitti qabaa jiraSadarkaa 1
  • Columbia University Irving Medical Center, New York
Umuriin 18 hanga 65 · Saalaa hunda · Haaromfame 06-Ado-2026 · NCT07403604

Non-Invasive Quantification of Liver Health in NASH (N-QUAN)

Namoota walitti qabaa jira
  • Icahn School of Medicine at Mount Sinai, New York
Umuriin 18 hanga 75 · Saalaa hunda · Haaromfame 19-Cam-2026 · NCT04054310

Diet and Meal Timing in Patients With Metabolic Dysfunction Associated Steatoic Liver Disease

Namoota walitti qabaa jiraHojjettoota fayyaa simatamoo
  • Weill Cornell Medicine, New York
Umuriin 18 hanga 65 · Saalaa hunda · Haaromfame 27-Gur-2026 · NCT05332613

High Fructose Diet, the Gut Microbiome, and Metabolic Health

Namoota walitti qabaa jiraHojjettoota fayyaa simatamoo
  • Mount Sinai Morningside, New York
Umuriin 25 hanga 45 · Saalaa hunda · Haaromfame 17-Mud-2025 · NCT06329544

Qorannoo Dhukkubaa Harkaa Steatotic magaalota biroo keessatti

Qorannoo biroo New York City keessatti

Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.